Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 Diabetes
Completed
Novo Nordisk A/S
Phase 3
2005-02-01
This trial is conducted in Europe and the United States of America (USA). The aim of this
trial is to compare the use of Insulin Detemir once a day (morning or evening) to NPH Insulin
once a day (evening) when added to treatment with oral antidiabetic drugs in patients with
Type 2 diabetes.
Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes
Completed
Novo Nordisk A/S
Phase 3
2004-09-01
This trial is conducted in Europe and the United States of America (USA). The purpose of this
study is to test whether insulin detemir is a safe and at least as effective alternative to
insulin glargine for the control of blood glucose in basal/bolus therapy in patients with
type I diabetes.
Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes
Completed
Novo Nordisk A/S
Phase 3
2004-09-01
This trial is conducted in Europe and the United States of America (USA). The purpose of this
study is to test whether insulin detemir is a safe and at least as effective alternative to
insulin glargine for the control of blood glucose in basal/bolus therapy in patients with
type 2 diabetes.
This preview shows a limited data set Subscribe for full access, or try a Trial
Insulin Detemir: Clinical Trials, Market Analysis, and Projections
Clinical Trials and Efficacy
Insulin detemir, a long-acting insulin analog, has undergone extensive clinical trials to establish its efficacy and safety in managing type 1 and type 2 diabetes.
Therapeutic Trials
A total of 10 clinical trials were conducted to support the efficacy and safety of insulin detemir. These trials included short-term and long-term studies in patients with type 1 and type 2 diabetes[1].
The clinical development program involved pharmacology trials in healthy subjects and patients with diabetes, as well as intermediate and long-term trials that provided the main evidence for its efficacy and safety[1].
Pharmacodynamics and Pharmacokinetics
In-vitro tests showed that insulin detemir was less potent than human insulin, with a potency 2- to 10-fold lower. However, in vivo studies in dogs and pigs showed it to be equipotent with human insulin, while it was less potent in other animal models[1].
Pharmacokinetic studies revealed a consistent and predictable profile across various populations, including healthy subjects, patients with type 1 and type 2 diabetes, children, elderly, and those with renal or hepatic impairment. The maximum plasma concentrations of insulin detemir are reached about 6 to 8 hours after subcutaneous administration[1].
Hypoglycemia and Weight Gain
Clinical trials demonstrated that insulin detemir reduces the risk of hypoglycemia compared to NPH insulin. A 26-week randomized trial showed a 47% reduction in all hypoglycemia and a 55% reduction in nocturnal hypoglycemia with insulin detemir[4].
Insulin detemir is also associated with less weight gain compared to conventional insulins. Studies showed that patients on insulin detemir had significantly less weight gain than those on NPH insulin[3][4].
Market Analysis
Market Size and Growth
The global insulin market, which includes insulin detemir, was valued at USD 19.45 billion in 2024 and is projected to grow at a CAGR of 3.74% from 2025 to 2030, reaching USD 23.21 billion by 2030[5].
Market Drivers
The increasing prevalence of diabetes, particularly type 2, is a major driver for the insulin market. Advances in formulations, such as long-acting insulins like insulin detemir, enhance treatment options and patient adherence[5].
Government initiatives and reimbursement policies improve access to insulin therapies, further expanding the market. Technological innovations in delivery devices and continuous glucose monitoring systems also drive market growth[5].
Market Segmentation
The long-acting insulin segment, which includes insulin detemir, accounted for 52.36% of the global insulin market in 2024 due to its longer duration of effect and the lesser number of injections required[5].
Competitive Landscape
Key players in the insulin market include Novo Nordisk A/S, Eli Lilly and Company, Sanofi, and others. The market is competitive, with companies focusing on innovation in insulin delivery mechanisms and personalized medicine approaches[2][5].
Market Projections
Growth Opportunities
Emerging markets with expanding healthcare infrastructure offer significant growth opportunities for insulin detemir. Investments in biosimilar research and partnerships with local distributors can help capitalize on these opportunities[2].
Innovations in insulin delivery systems, such as smart insulin pens and connected devices, and the development of formulations with improved pharmacokinetic profiles are expected to drive market growth[2].
Challenges
High competition from other insulin analogs, pricing pressures, and stringent regulatory requirements pose challenges to the market. Potential adverse effects and the need for regular monitoring also impact market adoption[2].
Cost-Effectiveness
Pharmacoeconomic models have shown that insulin detemir is cost-effective compared to human insulins and NPH insulin. It reduces healthcare costs through fewer complications and hospital visits, particularly in type 2 diabetes management[3].
Key Takeaways
Insulin detemir has been extensively tested in clinical trials, demonstrating its efficacy and safety in managing type 1 and type 2 diabetes.
The drug offers a predictable absorption pattern, minimal peak activity, and a prolonged duration of effect, reducing the risk of hypoglycemia and weight gain.
The global insulin market, driven by the increasing prevalence of diabetes and technological advancements, is expected to grow significantly by 2030.
Market growth for insulin detemir will be influenced by innovations in delivery systems, biosimilar developments, and expanding healthcare infrastructure in emerging markets.
FAQs
Q: What are the key benefits of insulin detemir compared to other insulins?
Insulin detemir offers a predictable absorption pattern, minimal peak activity, and a prolonged duration of effect. It reduces the risk of hypoglycemia and is associated with less weight gain compared to conventional insulins[2][4].
Q: How does the pharmacokinetic profile of insulin detemir compare to human insulin?
Insulin detemir has a lower potency than human insulin in vitro but is equipotent in some animal models. Its maximum plasma concentrations are reached about 6 to 8 hours after subcutaneous administration[1].
Q: What are the major drivers of the insulin detemir market?
The increasing prevalence of diabetes, advances in insulin formulations, government initiatives, and technological innovations in delivery devices are major drivers of the market[5].
Q: How cost-effective is insulin detemir compared to other insulin therapies?
Insulin detemir is cost-effective, particularly in reducing long-term complications and healthcare costs. Pharmacoeconomic models show it to be cost-effective compared to NPH insulin and human insulins[3].
Q: What are the challenges facing the insulin detemir market?
High competition, pricing pressures, stringent regulatory requirements, and the need for regular monitoring are some of the challenges impacting the market[2].
Sources
European Medicines Agency. Levemir, INN-insulin detemir. EPAR Scientific Discussion.
American Journal of Managed Care. Cost-Effectiveness of Insulin Analogs.
Diabetes Care. A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir or NPH Insulin Added to Oral Therapy for Type 2 Diabetes.
Grand View Research. Insulin Market Size, Share & Growth | Industry Report, 2030.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
